Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay

Jonathan Baden, George Green, Jennifer Painter, Katy Curtin, Jadwiga Markiewicz, Jennifer Jones, Tara Astacio, Susan Canning, Jedidiah Quijano, Wilson Guinto, Bradley C. Leibovich, Joel B. Nelson, Janet Vargo, Yixin Wang, Cao Wuxiong

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: Prostate specific antigen tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with prostate specific antigen greater than 4.0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARβ2 and APC) that indicate the presence of prostate cancer. Materials and Methods: The assay was evaluated in 337 post-digital rectal examination urine samples (178 cancer and 159 noncancer) collected prospectively at a total of 9 clinical sites. Samples were processed wholly or after division into equal portions. Subject prostate specific antigen was 2.0 to 10.0 ng/ml. All subjects underwent transrectal ultrasound guided needle biopsy with 6 or greater cores sampled. Detection of 1 or greater markers indicated positivity. Results: Methylation specific polymerase chain reaction assay performance was better in whole than in divided urine cohorts (p = 0.035). Assay AUC was 0.72 in the whole urine cohort and 0.67 in the combined population. These values were higher than those of prostate specific antigen alone using 4.0 ng/ml as the cutoff (p = 0.00 and 0.01, respectively). Moreover, the assay together with the Prostate Cancer Prevention Trial risk calculator or a standard nomogram significantly improved AUC in the whole urine cohort and the combined population vs predictive algorithms alone (p <0.05). Assay positive predictive value was 54% in whole urine cohort with prostate specific antigen 2.0 to 4.0 ng/ml and negative predictive value was 87% with prostate specific antigen 4.1 to 10.0 ng/ml. Assay positive predictive value was higher in subjects with all 3 methylation markers positive. Conclusions: These data demonstrate that this investigational assay used in conjunction with current screening algorithms may potentially add value to the biopsy decision making process.

Original languageEnglish (US)
Pages (from-to)1186-1193
Number of pages8
JournalJournal of Urology
Volume182
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Prostate-Specific Antigen
Methylation
Prostatic Neoplasms
Urine
Area Under Curve
Biopsy
Digital Rectal Examination
Polymerase Chain Reaction
Nomograms
Needle Biopsy
Population
Decision Making
Neoplasms

Keywords

  • biological
  • methylation
  • prostate
  • prostate-specific antigen
  • prostatic neoplasms
  • tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Baden, J., Green, G., Painter, J., Curtin, K., Markiewicz, J., Jones, J., ... Wuxiong, C. (2009). Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay. Journal of Urology, 182(3), 1186-1193. https://doi.org/10.1016/j.juro.2009.05.003

Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay. / Baden, Jonathan; Green, George; Painter, Jennifer; Curtin, Katy; Markiewicz, Jadwiga; Jones, Jennifer; Astacio, Tara; Canning, Susan; Quijano, Jedidiah; Guinto, Wilson; Leibovich, Bradley C.; Nelson, Joel B.; Vargo, Janet; Wang, Yixin; Wuxiong, Cao.

In: Journal of Urology, Vol. 182, No. 3, 09.2009, p. 1186-1193.

Research output: Contribution to journalArticle

Baden, J, Green, G, Painter, J, Curtin, K, Markiewicz, J, Jones, J, Astacio, T, Canning, S, Quijano, J, Guinto, W, Leibovich, BC, Nelson, JB, Vargo, J, Wang, Y & Wuxiong, C 2009, 'Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay', Journal of Urology, vol. 182, no. 3, pp. 1186-1193. https://doi.org/10.1016/j.juro.2009.05.003
Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J et al. Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay. Journal of Urology. 2009 Sep;182(3):1186-1193. https://doi.org/10.1016/j.juro.2009.05.003
Baden, Jonathan ; Green, George ; Painter, Jennifer ; Curtin, Katy ; Markiewicz, Jadwiga ; Jones, Jennifer ; Astacio, Tara ; Canning, Susan ; Quijano, Jedidiah ; Guinto, Wilson ; Leibovich, Bradley C. ; Nelson, Joel B. ; Vargo, Janet ; Wang, Yixin ; Wuxiong, Cao. / Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay. In: Journal of Urology. 2009 ; Vol. 182, No. 3. pp. 1186-1193.
@article{25c0f20ca9c4464a9701a32eeb10bfee,
title = "Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay",
abstract = "Purpose: Prostate specific antigen tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with prostate specific antigen greater than 4.0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARβ2 and APC) that indicate the presence of prostate cancer. Materials and Methods: The assay was evaluated in 337 post-digital rectal examination urine samples (178 cancer and 159 noncancer) collected prospectively at a total of 9 clinical sites. Samples were processed wholly or after division into equal portions. Subject prostate specific antigen was 2.0 to 10.0 ng/ml. All subjects underwent transrectal ultrasound guided needle biopsy with 6 or greater cores sampled. Detection of 1 or greater markers indicated positivity. Results: Methylation specific polymerase chain reaction assay performance was better in whole than in divided urine cohorts (p = 0.035). Assay AUC was 0.72 in the whole urine cohort and 0.67 in the combined population. These values were higher than those of prostate specific antigen alone using 4.0 ng/ml as the cutoff (p = 0.00 and 0.01, respectively). Moreover, the assay together with the Prostate Cancer Prevention Trial risk calculator or a standard nomogram significantly improved AUC in the whole urine cohort and the combined population vs predictive algorithms alone (p <0.05). Assay positive predictive value was 54{\%} in whole urine cohort with prostate specific antigen 2.0 to 4.0 ng/ml and negative predictive value was 87{\%} with prostate specific antigen 4.1 to 10.0 ng/ml. Assay positive predictive value was higher in subjects with all 3 methylation markers positive. Conclusions: These data demonstrate that this investigational assay used in conjunction with current screening algorithms may potentially add value to the biopsy decision making process.",
keywords = "biological, methylation, prostate, prostate-specific antigen, prostatic neoplasms, tumor markers",
author = "Jonathan Baden and George Green and Jennifer Painter and Katy Curtin and Jadwiga Markiewicz and Jennifer Jones and Tara Astacio and Susan Canning and Jedidiah Quijano and Wilson Guinto and Leibovich, {Bradley C.} and Nelson, {Joel B.} and Janet Vargo and Yixin Wang and Cao Wuxiong",
year = "2009",
month = "9",
doi = "10.1016/j.juro.2009.05.003",
language = "English (US)",
volume = "182",
pages = "1186--1193",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay

AU - Baden, Jonathan

AU - Green, George

AU - Painter, Jennifer

AU - Curtin, Katy

AU - Markiewicz, Jadwiga

AU - Jones, Jennifer

AU - Astacio, Tara

AU - Canning, Susan

AU - Quijano, Jedidiah

AU - Guinto, Wilson

AU - Leibovich, Bradley C.

AU - Nelson, Joel B.

AU - Vargo, Janet

AU - Wang, Yixin

AU - Wuxiong, Cao

PY - 2009/9

Y1 - 2009/9

N2 - Purpose: Prostate specific antigen tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with prostate specific antigen greater than 4.0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARβ2 and APC) that indicate the presence of prostate cancer. Materials and Methods: The assay was evaluated in 337 post-digital rectal examination urine samples (178 cancer and 159 noncancer) collected prospectively at a total of 9 clinical sites. Samples were processed wholly or after division into equal portions. Subject prostate specific antigen was 2.0 to 10.0 ng/ml. All subjects underwent transrectal ultrasound guided needle biopsy with 6 or greater cores sampled. Detection of 1 or greater markers indicated positivity. Results: Methylation specific polymerase chain reaction assay performance was better in whole than in divided urine cohorts (p = 0.035). Assay AUC was 0.72 in the whole urine cohort and 0.67 in the combined population. These values were higher than those of prostate specific antigen alone using 4.0 ng/ml as the cutoff (p = 0.00 and 0.01, respectively). Moreover, the assay together with the Prostate Cancer Prevention Trial risk calculator or a standard nomogram significantly improved AUC in the whole urine cohort and the combined population vs predictive algorithms alone (p <0.05). Assay positive predictive value was 54% in whole urine cohort with prostate specific antigen 2.0 to 4.0 ng/ml and negative predictive value was 87% with prostate specific antigen 4.1 to 10.0 ng/ml. Assay positive predictive value was higher in subjects with all 3 methylation markers positive. Conclusions: These data demonstrate that this investigational assay used in conjunction with current screening algorithms may potentially add value to the biopsy decision making process.

AB - Purpose: Prostate specific antigen tests have low specificity, which frequently results in unnecessary biopsy and typically limits screening to patients with prostate specific antigen greater than 4.0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARβ2 and APC) that indicate the presence of prostate cancer. Materials and Methods: The assay was evaluated in 337 post-digital rectal examination urine samples (178 cancer and 159 noncancer) collected prospectively at a total of 9 clinical sites. Samples were processed wholly or after division into equal portions. Subject prostate specific antigen was 2.0 to 10.0 ng/ml. All subjects underwent transrectal ultrasound guided needle biopsy with 6 or greater cores sampled. Detection of 1 or greater markers indicated positivity. Results: Methylation specific polymerase chain reaction assay performance was better in whole than in divided urine cohorts (p = 0.035). Assay AUC was 0.72 in the whole urine cohort and 0.67 in the combined population. These values were higher than those of prostate specific antigen alone using 4.0 ng/ml as the cutoff (p = 0.00 and 0.01, respectively). Moreover, the assay together with the Prostate Cancer Prevention Trial risk calculator or a standard nomogram significantly improved AUC in the whole urine cohort and the combined population vs predictive algorithms alone (p <0.05). Assay positive predictive value was 54% in whole urine cohort with prostate specific antigen 2.0 to 4.0 ng/ml and negative predictive value was 87% with prostate specific antigen 4.1 to 10.0 ng/ml. Assay positive predictive value was higher in subjects with all 3 methylation markers positive. Conclusions: These data demonstrate that this investigational assay used in conjunction with current screening algorithms may potentially add value to the biopsy decision making process.

KW - biological

KW - methylation

KW - prostate

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=68149170832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149170832&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.05.003

DO - 10.1016/j.juro.2009.05.003

M3 - Article

VL - 182

SP - 1186

EP - 1193

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -